Return to: Biotechnology News

Cancer Biomarkers Market worth 15,973.8 Million USD by 2020



According to a new market research report “Cancer Biomarker Market” is expected to reach USD 15,973.8 Million by 2020, at a CAGR of 11.6% from 2015 to 2020.

Cancer Biomarker Market by Tumor (Breast, Lung, Prostate) Type (Protein & Genetic Biomarkers) Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay) Application (Diagnostic, Drug Discovery, Prognostic) & Geography - Global Forecast to 2020

Browse 191 tables and 38 figures spread through 174 Pages and in-depth TOC on "Cancer Biomarker Market”
http://www.marketsandmarkets.com/Market-Reports/oncology-biomarkers-202.html
Early buyers will receive 10% free customization on this report.

This report analyzes and studies the major market drivers, restraints, opportunities, challenges, and trends in North America, Europe, Asia-Pacific, and Rest of the World. Cancer biomarkers are molecules secreted by a tumor or a specific response of the body to the presence of cancer. These are also referred as substance or processes which are indicative of the presence of cancer in the human body, which enhances the cancer detection and facilitate high speed, non-invasive diagnosis using genomics and proteomics based tools. The cancer biomarkers are used for drug discovery and development, diagnostics, personalized medicine, and therapeutics.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=202

In this report, the Cancer Biomarkers Market is segmented on the basis of type of biomarkers, tumor type, profiling technologies, applications, and region. Based on biomarker type, the market is segmented into protein biomarkers, genetic biomarkers, and others which include viral, cell, and carbohydrate biomarkers. Based on tumor type, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, and other type of cancers such as Gastrointestinal Stromal Tumors (GIST), lung, ovarian, bladder, pancreatic, kidney, melanoma, and leukemia cancers. Based on profiling technologies, the market is segmented into omics technologies, imaging technologies, immunoassays, cytogenetics, and bioinformatics. Based on applications, the market is segmented into diagnostics, drug discovery and development, prognostics, risk assessment, and others which include surrogate endpoints, recurrence, personalized medicine, and therapeutics. This report also discusses key market drivers, restraints, opportunities, and challenges for this market and its submarkets. The global Cancer Biomarkers Market is expected to reach USD 15,973.8 Million by 2020, at a CAGR of 11.6% from 2015 to 2020.

The diagnostics segment is the largest application of cancer biomarkers which includes tests that access the biological makeup of individuals at the molecular level to determine the individual’s predisposition to a particular disease or condition and diagnose it. With the introduction of new technologies and applications, this is one of the most rapidly advancing areas of research and medicine. The rising prevalence of cancer; increasing demand for advanced diagnostics tests; increased awareness and acceptance of diagnostics tests; advancement in technologies; and the need for early-stage cancer diagnosis further propels the growth of this market.

Report Sample Pages: http://www.marketsandmarkets.com/requestsample.asp?id=202

In 2014, North America accounted for the largest share of the Cancer Biomarkers Market, followed by Europe, Asia-Pacific, and RoW. The major shares of North America and Europe are primarily attributed to rising prevalence of cancer, faster adoption of advanced technologies like advanced high throughput technologies, increasing research studies on discovery and development of novel biomarkers, presence of large number of pharmaceutical companies, rising funding and investment from public and private organizations, presence of key players in these regions, and rising applications of biomarkers in patient stratification and drug development process. The future growth of the Cancer Biomarkers Market will be driven by the Asia-Pacific region, owing to the rising incidence of cancer in this region, increasing use of biomarker tests for diagnosis purposes, expansions of major pharmaceutical companies in emerging Asian economies, and government support to research institutes and universities. However, poorly suited regulatory and reimbursement systems for biomarker tests and requirement of high capital investments for biomarker discovery and development are expected to restrain the growth of this market during the forecast period.

The prominent players in the Cancer Biomarkers Market are Abbott Laboratories (U.S.), Affymetrix Inc. (U.S.), Roche Diagnostics Ltd. (Switzerland), Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), Agilent Technologies (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck & Co. Inc. (U.S.), Becton Dickinson and Company (U.S.), and Hologic Inc. (U.S.).

Contact:
Mr. Rohan
MarketsandMarkets ™
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
1-888-600-6441
Email: sales@marketsandmarkets ...

News Release: Cancer Biomarkers Market worth 15,973.8 Million USD by 2020
Submitted on: July 12, 2017 07:29:06 AM
Submitted by: rosy wills
On behalf of: www.marketsandmarkets.com/Market-Reports/oncology-biomarkers-202.html
advertisement